Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 24, 2006. The report specifically addresses the vesting of Performance Share Plan Awards granted on December 3, 2002, which concluded a three-year performance period on December 31, 2005.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation mechanics and share transactions.
Material Changes
The primary material change reported is the vesting of 50% of the Performance Share Plan Awards granted in 2002. This vesting was contingent on two performance conditions:
- Total Shareholder Return (TSR): The company was required to rank at least 50th against FTSE 100 index companies. This condition was not met, and no awards vested under this criterion.
- Earnings Per Share (EPS) Growth: The company was required to achieve EPS growth (excluding currency and exceptional items) at least nine percentage points higher than the increase in the UK Retail Price Index over the three-year period. This condition was achieved in full.
Management Commentary and Unusual Items
The Remuneration Committee determined the vesting outcome on February 23, 2006. The filing details specific share transactions by Executive Directors to meet tax liabilities:
- Dr. JP Garnier: Received 35,000 shares but elected to defer the award until retirement; no shares were sold.
- Mr. J S Heslop: Sold 1,025 shares at GBP 14.65 per share.
- Dr. T Yamada: Sold 4,119 ADSs at $51.3499 per ADS.
The filing contains no forward-looking guidance, risk factors, or management commentary regarding the company's broader business outlook.
Investor Verification Checklist
- Verify the specific EPS growth figures and UK Retail Price Index data for the 2003-2005 period to confirm the EPS condition achievement.
- Confirm the exact number of shares vested for each executive director beyond the tax sale figures provided.
- Review the company's annual report (Form 20-F) for the full financial impact of the performance share plan vesting on the 2005 fiscal year.